Emergent Biosolutions Inc (EBS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Emergent Biosolutions Inc Stock (EBS) Company Profile

Emergent Biosolutions Inc

Healthcare (1152)

240-631-3200

300 PROFESSIONAL DR, GAITHERSBURG, MD

@emergentbiosolu

Prossima data di guadagno

Ultimi documenti SEC

EBS's Discussions on Twitter

Confronta EBS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
EBS Emergent Biosolutions Inc	8.14	425.21M	1.02B	-757.20M	-257.90M	-14.76
ZTS Zoetis Inc	148.20	66.22B	9.39B	2.62B	2.22B	5.81
TAK Takeda Pharmaceutical Co Adr	15.10	48.29B	29.96B	957.25M	4.77B	0.304
HLN Haleon Plc Adr	9.81	43.99B	14.26B	1.98B	2.47B	0.4347
TEVA Teva Pharmaceutical Industries Ltd Adr	19.93	22.45B	16.70B	-157.13M	1.19B	-0.155
UTHR United Therapeutics Corp	405.02	17.93B	2.99B	1.21B	1.13B	25.06

Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-30	Iniziato	H.C. Wainwright	Buy
2024-08-22	Iniziato	Rodman & Renshaw	Buy
2024-03-07	Aggiornamento	The Benchmark Company	Hold → Buy
2023-11-20	Ripresa	JP Morgan	Underweight
2023-08-29	Downgrade	The Benchmark Company	Buy → Hold
2023-04-10	Aggiornamento	The Benchmark Company	Hold → Buy
2023-03-17	Downgrade	JP Morgan	Neutral → Underweight
2022-11-10	Downgrade	The Benchmark Company	Buy → Hold
2022-04-29	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2022-01-20	Aggiornamento	The Benchmark Company	Hold → Buy
2021-11-08	Downgrade	The Benchmark Company	Buy → Hold
2021-05-05	Downgrade	Argus	Buy → Hold
2021-04-07	Iniziato	The Benchmark Company	Buy
2021-02-24	Aggiornamento	Chardan Capital Markets	Neutral → Buy
2021-02-19	Downgrade	Chardan Capital Markets	Buy → Neutral
2021-01-08	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-09-14	Ripresa	JP Morgan	Neutral
2020-07-31	Reiterato	Chardan Capital Markets	Buy
2019-09-12	Iniziato	Guggenheim	Buy
2019-09-04	Aggiornamento	Wells Fargo	Market Perform → Outperform
2018-11-02	Aggiornamento	Goldman	Neutral → Buy
2018-08-03	Reiterato	Chardan Capital Markets	Buy
2018-06-13	Iniziato	Argus	Buy
2018-04-25	Downgrade	Wells Fargo	Outperform → Market Perform
2018-01-24	Iniziato	Goldman	Neutral
2018-01-16	Reiterato	Chardan Capital Markets	Buy
2016-06-28	Reiterato	Singular Research	Buy
2016-04-15	Iniziato	Chardan Capital Markets	Buy
2016-03-28	Iniziato	Singular Research	Buy
2016-02-19	Iniziato	Wells Fargo	Outperform
2014-05-15	Iniziato	Summer Street Research	Buy
2011-05-31	Reiterato	WBB Securities	Strong Buy
2011-01-10	Reiterato	Wedbush	Outperform
2010-11-05	Reiterato	Wedbush	Outperform
2010-08-18	Aggiornamento	WBB Securities	Buy → Strong Buy
2010-08-06	Reiterato	Caris & Company	Buy

Mostra tutto

Emergent Biosolutions Inc Borsa (EBS) Ultime notizie

Emergent Biosolutions Inc Azioni (EBS) Dati Finanziari

Emergent Biosolutions Inc (EBS)

Emergent Biosolutions Inc Stock (EBS) Company Profile

Confronta EBS con altri titoli

Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades

Emergent Biosolutions Inc Borsa (EBS) Ultime notizie

Emergent BioSolutions Secures $56 Million Contract Modification - MSN

Nomura Holdings Inc. Sells 130,800 Shares of Emergent Biosolutions Inc. $EBS - MarketBeat

H.C. Wainwright reiterates Buy rating on Emergent BioSolutions stock amid $56M contract - Investing.com

Emergent Biosolutions awarded $30 million contract modification for CYFENDUS - MSN

Trexquant Investment LP Cuts Stock Position in Emergent Biosolutions Inc. $EBS - MarketBeat

Emergent BioSolutions secures $56 million U.S. government contract By Investing.com - Investing.com Australia

Emergent BioSolutions secures $56 million U.S. government contract - Investing.com

Emergent BioSolutions (EBS) Secures $56 Million Contract for ACA - GuruFocus

Emergent gets U.S. contract update for ACAM2000 smallpox & mpox vaccine - MarketScreener

$120M Total Sales: Emergent's Smallpox Vaccine ACAM2000 Scores New $56M U.S. Government Contract - Stock Titan

Emergent Biosolutions (NYSE:EBS) Receives Buy Rating from HC Wainwright - MarketBeat

H.C. Wainwright Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛

Emergent BioSolutions’ AIGIV Study: A Potential Game-Changer for Inhalational Anthrax Treatment - MSN

Is Emergent BioSolutions Inc. trending in predictive chart modelsTrade Analysis Report & Daily Volume Surge Signals - Newser

How to build a custom watchlist for Emergent BioSolutions Inc.Watch List & Daily Chart Pattern Signals - Newser

Will earnings trigger a reversal in Emergent BioSolutions Inc.2025 Price Momentum & Fast Gain Stock Trading Tips - Newser

What’s the beta of Emergent BioSolutions Inc. stockWeekly Risk Summary & Advanced Technical Signal Analysis - خودرو بانک

Will Emergent BioSolutions Inc. face regulatory challenges2025 Market Overview & Smart Swing Trading Alerts - خودرو بانک

OMERS ADMINISTRATION Corp Acquires 114,500 Shares of Emergent Biosolutions Inc. $EBS - MarketBeat

Is Emergent BioSolutions Inc. showing insider buyingMarket Performance Report & Verified Technical Signals - خودرو بانک

Will Emergent BioSolutions Inc. outperform the marketM&A Rumor & Daily Stock Trend Reports - Newser

Smart tools for monitoring Emergent BioSolutions Inc.’s price action2025 Fundamental Recap & AI Based Buy and Sell Signals - Newser

Emergent BioSolutions Inc. stock retracement – recovery analysisTrade Risk Assessment & Low Volatility Stock Suggestions - Newser

Real time scanner hits for Emergent BioSolutions Inc. explained2025 Technical Patterns & Risk Controlled Swing Alerts - Newser

Backtesting results for Emergent BioSolutions Inc. trading strategies2025 Analyst Calls & Momentum Based Trading Signals - Newser

Is Emergent BioSolutions Inc. forming a bottoming basePortfolio Return Summary & Capital Protection Trade Alerts - Newser

Emergent BioSolutions at Wells Fargo Conference: Strategic Growth Insights By Investing.com - Investing.com Canada

Building trade automation scripts for Emergent BioSolutions Inc.2025 Valuation Update & Fast Exit/Entry Strategy Plans - Newser

Can swing trading help recover from Emergent BioSolutions Inc. lossesMarket Performance Summary & Fast Exit and Entry Trade Guides - Newser

Emergent BioSolutions at Wells Fargo Conference: Strategic Growth Insights - Investing.com

Sector ETF performance correlation with Emergent BioSolutions Inc.Earnings Growth Report & High Accuracy Swing Trade Signals - Newser

Heatmap analysis for Emergent BioSolutions Inc. and competitorsLong Setup & Community Supported Trade Ideas - Newser

What data driven models say about Emergent BioSolutions Inc.’s futureJuly 2025 Reactions & Verified Swing Trading Watchlist - Newser

Real time breakdown of Emergent BioSolutions Inc. stock performanceWeekly Trend Recap & Capital Efficiency Focused Ideas - Newser

Is Emergent BioSolutions Inc. meeting your algorithmic filter criteriaMarket Performance Report & Advanced Technical Signal Analysis - Newser

Can Emergent BioSolutions Inc. continue delivering strong returnsBond Market & AI Optimized Trade Strategies - خودرو بانک

Charles Schwab Investment Management Inc. Has $2.84 Million Stock Holdings in Emergent Biosolutions Inc. $EBS - MarketBeat

Order flow analysis tools used on Emergent BioSolutions Inc.July 2025 Weekly Recap & Verified Momentum Stock Ideas - Newser

Tools to monitor Emergent BioSolutions Inc. recovery probabilityPortfolio Gains Summary & Growth Focused Entry Point Reports - Newser

Emergent BioSolutions’ AIGIV Study: A Potential Game-Changer for Anthrax Treatment - MSN

Ranking Emergent BioSolutions Inc. among high performing stocks via toolsJuly 2025 Retail & Capital Efficiency Focused Ideas - Newser

Is Emergent BioSolutions Inc. stock bottoming outJuly 2025 News Drivers & Weekly Breakout Opportunity Watchlist - Newser

H.C. Wainwright reiterates Buy rating on Emergent BioSolutions stock with $15 target - Investing.com Canada

Does Emergent BioSolutions Inc. stock benefit from AI growth2025 Year in Review & Daily Market Momentum Tracking - خودرو بانک

Mineralys’ strategic stock sale; Gilead, Shoreline partnership ends - Endpoints News

What high frequency data says about Emergent BioSolutions Inc.July 2025 Short Interest & Weekly Chart Analysis and Guides - Newser

Can Emergent BioSolutions Inc. hit a new high this monthBear Alert & Expert Curated Trade Setups - Newser

Tools to assess Emergent BioSolutions Inc.’s risk profile2025 Price Action Summary & Free Real-Time Volume Trigger Notifications - Newser

Emergent: HC Wainwright & Co. reiterates the 'Buy' Rating, The Target Price is $15 - AInvest

Emergent BioSolutions (EBS) Maintains Buy Rating and Price Targe - GuruFocus

Is Emergent BioSolutions Inc. stock reversal real or fake2025 Trading Volume Trends & Safe Entry Zone Tips - Newser

Emergent Biosolutions Inc Azioni (EBS) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a EBS